Immunic to Showcase Advances in Neurology at June Conferences
Immunic's Participation in Upcoming Conferences
Immunic, Inc. (Nasdaq: IMUX), a biotechnology firm focused on pioneering oral therapies for neurologic conditions, is set to participate in several critical conferences this June. These events will allow the company to provide updates on its ongoing projects and engage with potential investors and industry leaders.
H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit
Date: June 15-16, 2026
Location: New York, NY (with virtual access)
Key Participants: Erik Lundgren (CEO) and Jason Tardio (COO)
The first event on the agenda is the H.C. Wainwright Neuro Perspectives Expert Summit, scheduled for June 15-16. Both Lundgren and Tardio will participate in a fireside chat, discussing the company's strategic vision and advancements. Attendees can expect to access a pre-recorded presentation starting June 15 at 7 AM ET through the conference's website. Following the conference, an archived version of the discussion will be available on Immunic's official site for up to 90 days.
Additionally, one-on-one meetings with investors are slated throughout the summit. Interested parties should coordinate with H.C. Wainwright representatives or Jessica Breu, Immunic's Vice President of Investor Relations, to secure a meeting time.
BIO International Convention 2026
Date: June 22-25, 2026
Location: San Diego, CA
Next up is the BIO International Convention, one of the most significant annual events in the biotech industry. Immunic's management team will take part in various partnering activities aimed at fostering collaborations that can propel its innovative treatments forward. Individuals wishing to arrange discussions should utilize the convention’s partnering portal or reach out directly to Jessica Breu for assistance.
EFMC-ACSMEDI Symposium
Date: June 22-25, 2026
Location: Dublin, Ireland
Presenter: Christian Gege, Ph.D., Global Head of Intellectual Property
Concurrently, Christian Gege will represent Immunic at the EFMC-ACSMEDI Medicinal Chemistry Frontiers Symposium, presenting recent findings related to IMU-856. This includes an oral and poster presentation titled Discovery of IMU-856, a Selective Sirtuin 6 Modulator with Novel Binding Characteristics for Gastrointestinal Disease Treatment. Attendees can find the presentation in the
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.